about
The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergyDNA vaccines against cancer: from genes to therapy.CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells.DNA vaccination: a potential weapon against infection and cancer.Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins.Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK.Plant virus particles carrying tumour antigen activate TLR7 and Induce high levels of protective antibody.Immunotherapy of hematologic malignancy.Chronic lymphocytic leukemia: revelations from the B-cell receptor.Tumor vaccines.Engineering DNA vaccines that include plant virus coat proteins.Update on tumor vaccines.Vaccination Expands Antigen-Specific CD4+ Memory T Cells and Mobilizes Bystander Central Memory T CellsLectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma.DNA fusion gene vaccines against cancer: from the laboratory to the clinic.Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia.Update on cancer vaccines.Evidence for the overexpression of the VH4-34 (VH4.21) Ig gene segment in the normal adult human peripheral blood B cell repertoire.Expression of anti-DNA antibodies.DNA vaccines: precision tools for activating effective immunity against cancer.A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer.Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells.Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.PEITC-mediated inhibition of mRNA translation is associated with both inhibition of mTORC1 and increased eIF2α phosphorylation in established cell lines and primary human leukemia cells.DNA vaccines against cancer come of age.The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia.DNA fusion vaccines enter the clinic.Anti-idiotypic therapy of leukemias and lymphomas.The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia.Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor.Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.Immunogenetic analysis of the heavy chain variable regions of IgE from patients allergic to peanuts.IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.Early stages in the ontogeny of small B-cell lymphomas: genetics and microenvironment.Polycythaemia rubra vera and hairy cell leukaemia in the same patient: studies on the spleen.DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.VH gene sequences from a novel tropical splenic lymphoma reveal a naive B cell as the cell of origin.DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance.
P50
Q26865760-5E960601-741F-4D42-83B3-C5C5570FC182Q33822028-A4D138CE-4D01-41EA-9398-AFF7C5081A3CQ33956997-20E2DE63-6765-425D-8DEC-EC4389CB239AQ34029409-F2DC7AB4-27AC-4126-8780-8098BC29B028Q34242413-A1BB7991-7442-4698-9FA4-C85FD32AE928Q34276522-793CDB39-0A7F-4C67-8FE6-7AAFD317E35EQ34508337-81B98F16-2B59-4392-9680-DFDEB3FD9A26Q35096289-881F33C5-A7C3-4877-9516-8E2B44A9C858Q35591452-93959C8C-3B3A-4B70-976C-56FDC52A0084Q35667038-91BBC56F-52CC-4109-9022-6371AC913582Q35671699-4849374B-B506-42A2-B2D5-732D355877F9Q35680992-839E4582-257D-4736-8439-0FEC8A14E00EQ35713140-1C9F50BE-0092-44FC-BAC0-57EDD40CC4D6Q35762582-13AFD48D-86B4-4489-B217-B42F55E9C14FQ35786734-EB3AD410-046B-4810-AD6D-75AB2951B6EEQ35826392-B91FC692-8589-48B5-B3C7-8ECB84017FFBQ35863376-4749891A-BD74-4BF5-9590-BB3C126B2FE6Q36085962-619EDB3C-9546-42DC-8E50-73AF32F3BD7EQ36285750-30DE5A7E-1447-4409-B68C-486360837A08Q36704551-4A4258D8-2160-4B68-A983-C24140EF4F31Q36882524-1B7830A5-D2EE-4B12-A848-09E6B6440192Q37064852-EA817F1F-1BA4-4FA2-8D19-50D7AF953778Q37078963-C4B36A17-2351-44B5-AE4B-E0A93F730D51Q37360579-2C21C5D8-1EB5-43B7-B09E-17334292ABC4Q37671730-3994C179-BB48-4160-903E-E3FE45D6FDB4Q37688853-E4990184-06F8-47E8-9280-8779739592CDQ37695936-38F41DCA-894E-453A-8C29-0605A48B6844Q37785274-A67B26EE-6884-4721-B98E-BFD050E0772EQ37885288-4E499719-ED76-4959-B19D-D6D4C0C11526Q38137853-9D9BB74F-291F-4C98-A673-E2B54AEB9954Q38232479-CD6F0259-1206-45AD-BA42-EB3891EF36D2Q38306094-B151B455-88D0-4080-A903-8657C10FCB86Q38825994-1D98C19A-11D8-497C-A834-8AD0DE2B7A54Q39115771-79B608C1-2E88-4F73-8DC0-E0817C4CF69FQ39150343-A4E04BF0-1714-4F50-BB67-3C35D19B3A41Q39230986-9D95B70C-B3D7-4435-9016-23C774CD9915Q39499086-E893FFDE-5BAC-49E9-A49E-25E54DEF51EBQ39538214-8B04AB39-E9C1-4214-BE0C-56779CD443A2Q39630829-2FFB562C-863A-42DB-A455-0A6A82A76E8DQ39978708-D1345E1A-B566-4D8B-B459-26872DAAD64E
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Freda K Stevenson
@nl
Freda K Stevenson
@sl
Freda K. Stevenson
@en
Freda K. Stevenson
@es
type
label
Freda K Stevenson
@nl
Freda K Stevenson
@sl
Freda K. Stevenson
@en
Freda K. Stevenson
@es
prefLabel
Freda K Stevenson
@nl
Freda K Stevenson
@sl
Freda K. Stevenson
@en
Freda K. Stevenson
@es
P1006
P214
P244
P1006
P106
P1153
7102932460
P21
P213
0000 0000 4452 0375
P214
P244
no2004069360
P31
P496
0000-0002-0933-5021
P734
P735
P7859
lccn-no2004069360